Participants experiencing bleeding events · children with acute postoperative pain
It is very uncertain whether ketorolac changes participants experiencing bleeding events compared with placebo (very low certainty).
1 finding from 1 review
At least 50% reduction in pain · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
Intravenous diclofenac may leads to higher number of participants with at least 50% pain relief at 4 hours compared with placebo (low certainty).
2 findings from 1 review
Median (mean) time to use of rescue medication · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
1 finding from 1 review
Number of participants using rescue medication over 4 to 6 hours postinterventions · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
Intravenous diclofenac may leads to lower number of participants using rescue medication over 4 to 6 hours… compared with placebo (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
Intravenous diclofenac showed no clear difference in number of participants reporting any adverse event compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · Adults (mean study ages 25 to 55 years) with acute postoperative pain after dental, mixed minor, abdominal, or orthopedic surgeries
Intravenous diclofenac showed no clear difference in number of participants experiencing a serious adverse event compared with placebo (low certainty).
1 finding from 1 review
No nausea or vomiting over trial period · cancer patients
Olanzapine probably leads to higher no nausea or vomiting over trial period compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 1.98 [1.59, 2.47]
Studies not reported
Moderate
Serious adverse events · cancer patients
Olanzapine showed no clear difference in serious adverse events compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 2.46 [0.48, 12.55]
Studies not reported
Low
Participant preference ‐ wish to use drug in next treatment · cancer patients
Olanzapine showed no clear difference in participant preference ‐ wish to use drug in next treatment compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 1.43 [0.97, 2.09]
Studies not reported
Moderate
Quality of life · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change · cancer patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events · cancer patients
Olanzapine showed no clear difference in other adverse events compared with placebo/no treatment (low certainty).
1 finding from 1 review
RR 1.71 [0.99, 2.96]
Studies not reported
Low
Somnolence/fatigue · cancer patients
Olanzapine probably leads to higher somnolence/fatigue compared with placebo/no treatment (moderate certainty).
1 finding from 1 review
RR 2.33 [1.3, 4.18]
Studies not reported
Moderate
Participant‐reported pain relief of 50% or greater · adults with fibromyalgia
Mirtazapine showed no clear difference in participant‐reported pain relief of 50% or greater (substantial… compared with placebo (low certainty).
1 finding from 1 review
Safety Any serious adverse event · adults with fibromyalgia
It is very uncertain whether mirtazapine changes safety: serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with fibromyalgia
Mirtazapine showed no clear difference in tolerability: withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with fibromyalgia
Mirtazapine may leads to higher participant‐reported pain relief of 30% or greater (moderate… compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported sleep problems (scale: 0 to 28; higher scores indicate more sleep problems) · adults with fibromyalgia
Mirtazapine showed no clear difference in participant‐reported sleep problems (scale: 0 to 28; higher scores… compared with placebo (low certainty).
1 finding from 1 review
Somnolence · adults with fibromyalgia
Mirtazapine may leads to higher somnolence compared with placebo (low certainty).
1 finding from 1 review
Weight gain · adults with fibromyalgia
Mirtazapine may leads to higher weight gain compared with placebo (low certainty).
1 finding from 1 review